CROSS COUNTRY HEALTHCARE INC

Cross Country Healthcare announced that its special meeting to approve the merger with KL Criss Cross Intermediate, LLC is scheduled for July 16, 2026. The company has received demand letters and faces two lawsuits (Malone Action and Walsh Action) from purported stockholders alleging material omissions and misrepresentations in its definitive proxy statement. While denying the claims, Cross Country Healthcare has decided to voluntarily supplement the proxy statement to alleviate risks and uncertainties.

Cross Country Healthcare announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its previously disclosed merger with KL Criss Cross Intermediate, LLC, and the sale of its locums business division, expired on June 22, 2026. This satisfies a major condition for the closing of the transactions, which are still subject to other customary closing conditions. The Merger is anticipated to close in the third quarter of 2026, with a special shareholder meeting scheduled for July 16, 2026, to approve the Merger.

Cross Country Healthcare, Inc. announced it has entered into an Agreement and Plan of Merger with KL Criss Cross Intermediate, LLC, under which it will become a wholly-owned subsidiary. This strategic move comes as the company reported a significant increase in net loss for Q1 2026, reaching $(4.27) million, compared to $(0.49) million in Q1 2025. Revenue from services also saw a decline, falling to $241.06 million from $293.41 million year-over-year.

Cross Country Healthcare announced its first quarter 2026 financial results, reporting a revenue of $241.1 million, an 18% decrease year-over-year, and a net loss of $4.3 million. The company also confirmed a pending merger with KL Criss Cross Intermediate, LLC, expected to close in the third quarter, leading to the cancellation of its earnings conference call. Despite the year-over-year declines, the company noted sequential revenue growth and positive cash flow from operations.

Cross Country Healthcare, Inc. has entered into a definitive agreement to be acquired by Knox Lane, a growth-oriented investment firm, in an all-cash transaction valued at $437 million. Shareholders will receive $13.25 per share, representing a significant premium of approximately 31% to the closing price on May 6, 2026, and a 45% premium to the 90-day volume-weighted average trading price. The transaction is anticipated to close in the third quarter of 2026, after which Cross Country Healthcare will become a privately held company and its shares will cease trading on Nasdaq.

Cross Country Healthcare, Inc. announced that it issued a press release on April 17, 2026. This press release is included as Exhibit 99.1 to the Current Report on Form 8-K. The information provided in Item 7.01, including the exhibit, is furnished and not considered "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.